Financial Report: Amgen 1Q

Amgen 1Q

1Q Revenues: $3.3 billion (-8%)

1Q Earnings: $1.0 billion (-7%)

Comments: Total product sales were down 8% to $3.2 billion, partly reflecting the negative impact of foreign exchange. Sales in the U.S. were $2.5 billion (-10%). International sales were $736 million (-2%). Worldwide sales of Aranesp were $626 million (-18%). Sales of Epogen were $565 million (+2%). Combined worldwide sales of Neulasta and Neupogen were down 1% to $1.1 billion. Sales of Enbrel were down 20% to $758 million. Sales of Sensipar were up 11% to $148 million.